Pulmatrix (PULM) News Today → Pentagon contract could send this $2 AI stock soaring (From Behind the Markets) (Ad) Free PULM Stock Alerts $2.09 +0.07 (+3.47%) (As of 04/24/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlinePulmatrix (NASDAQ:PULM) Coverage Initiated by Analysts at StockNews.comamericanbankingnews.com - April 24 at 2:22 AMPULM Stock Earnings: Pulmatrix Beats EPS, Beats Revenue for Q4 2023investorplace.com - March 28 at 11:31 PMPulmatrix Inc.: Pulmatrix Announces Year-End and Q4 2023 Financial Results and Provides Corporate Updatefinanznachrichten.de - March 28 at 11:46 AMPulmatrix Announces Year-End and Q4 2023 Financial Results and Provides Corporate Updateprnewswire.com - March 28 at 9:05 AMCipla Ltd CIPLAmorningstar.com - February 15 at 11:00 PMFive things: Boston State of the City, high business costs, biotech shutdowns and Boston Calling headlinersbizjournals.com - January 10 at 7:51 AMPulmatrix shuts down study, explores salebizjournals.com - January 9 at 3:43 PMPulmatrix To Stop PUR1900 Phase 2B Study Patient Enrollment And Closing The Studynasdaq.com - January 8 at 1:11 PMPulmatrix Closes Study Of Fungal Lung Infection Treatment, Explores Strategic Alternativesmarketwatch.com - January 8 at 1:11 PMPulmatrix Announces Stopping the PUR1900 Phase 2B Study Patient Enrollment and Closing the Study, in Agreement With Partner Cipla, to Preserve Cash and Facilitate Pursuit of Strategic Alternativesfinance.yahoo.com - January 8 at 1:11 PMStocks in news: Titan, Marico, Bajaj Auto, Adani Wilmar, Tata Steelmsn.com - January 8 at 12:42 AMStock Market Today: Dr Reddy's, Titan, And Reliance Power Shares In Focusmsn.com - January 8 at 12:42 AMPulmatrix Inc PULMmorningstar.com - November 12 at 9:08 AMPulmatrix Down on Q3 Resultsbaystreet.ca - November 9 at 1:38 PMPulmatrix GAAP EPS of -$1.03, revenue of $1.75Mmsn.com - November 9 at 1:38 PMPulmatrix Announces Third Quarter 2023 Financial Results and Provides Corporate Updatefinance.yahoo.com - November 9 at 1:38 PMAspergillosis Treatment Research Report 2023finance.yahoo.com - October 23 at 3:27 PMPulmatrix Receives Study May Proceed Letter From FDA For Phase 2 Study To Evaluate PUR3100markets.businessinsider.com - September 19 at 9:49 AMPulmatrix Announces FDA Acceptance of IND Application for PUR3100 to Treat Acute Migrainefinance.yahoo.com - September 19 at 9:49 AMPulmatrix, Inc. (PULM) Could Find a Support Soon, Here's Why You Should Buy the Stock Nowmsn.com - September 11 at 3:15 PMPulmatrix Announces Publication on Physiologically Based Pharmacokinetic Modelling of Potential Drug-Drug Interactions with PUR1900, Orally Inhaled Itraconazolefinance.yahoo.com - August 23 at 6:11 PMPulmatrix, Inc.: Pulmatrix Announces Second Quarter 2023 Financial Results and Provides Corporate Updatefinanznachrichten.de - August 10 at 2:43 PMPulmatrix GAAP EPS of -$1.04, revenue of $1.84Mmsn.com - August 10 at 2:43 PMPulmatrix Announces Second Quarter 2023 Financial Results and Provides Corporate Updatefinance.yahoo.com - August 10 at 9:42 AMPulmatrix Announces Submission of IND Application to FDA to Initiate a Phase 2 Trial of Investigational Drug PUR3100 to Treat Acute Migrainefinance.yahoo.com - July 11 at 1:44 PMPulmatrix Presents PUR3100 Phase 1 Data at the 65th Annual Meeting of the American Headache Societyfinance.yahoo.com - June 15 at 12:25 PMPulmatrix Selected to Present at the Annual Biotechnology Innovation Organization (BIO) International Conventionfinance.yahoo.com - May 24 at 12:18 PMH.C. Wainwright Remains a Buy on Pulmatrix (PULM)markets.businessinsider.com - May 15 at 10:58 AMPulmatrix GAAP EPS of -$1.22, revenue of $1.5Mmsn.com - May 12 at 2:19 PMPulmatrix Announces First Quarter 2023 Financial Results and Provides Corporate Updatefinance.yahoo.com - May 12 at 9:18 AMInjectable Drug Delivery Technology Market: Latest Innovations, Drivers and Industry Key Events 2023-2031marketwatch.com - May 9 at 4:46 AMPulmatrix Supports World Asthma Day 2023finance.yahoo.com - May 2 at 2:54 PMPulmatrix, Inc. (PULM) stock historical prices & data – Yahoo Financesg.finance.yahoo.com - April 20 at 8:51 AMPulmatrix Announces Year-End and Q4 Financial 2022 Results and Provides Corporate Updatefinance.yahoo.com - March 30 at 1:23 PMInjectable Drug Delivery Devices Market is Booming by Size, Revenue, Trend and Top Growing Companies 2023-2028marketwatch.com - February 27 at 5:51 PMGlobal Targeted Drug Delivery System Market 2023 Global Share, Key Country Analysis and Forecasts 2030 By VMReportsmarketwatch.com - February 18 at 3:29 PMPulmatrix Announces First Patient Dosed in Phase 2b Study of PUR1900 for Treatment of Allergic Bronchopulmonary Aspergillosis (ABPA) in Subjects with Asthmafinance.yahoo.com - February 6 at 9:59 AMPulmatrix to Host Key Opinion Leader Webinar "PUR3100 for the Treatment of Acute Migraine: Unlocking the Potential of DHE Treatment"finance.yahoo.com - January 25 at 10:19 AMPulmatrix, Inc. (PULM) Stock Historical Prices & Data - Yahoo Financefinance.yahoo.com - December 17 at 8:44 AMPulmatrix Announces Third Quarter 2022 Financial Results and Provides Corporate Updatefinance.yahoo.com - November 10 at 4:03 PMPULM.A - Pulmatrix Inc | Stock Price & Latest News | Reutersreuters.com - October 7 at 3:39 AMPulmatrix, Inc. (PULM) Stock Price Today, Quote & News - Seeking Alphaseekingalpha.com - October 5 at 4:28 PMPulmatrix Announces Patient Dosing Completed for its Novel Inhaled Therapy PUR3100 for Acute Migraine - Yahoo Financefinance.yahoo.com - September 26 at 12:42 PMPulmatrix Announces Patient Dosing Completed for its Novel Inhaled Therapy PUR3100 for Acute Migrainefinance.yahoo.com - September 26 at 12:42 PMPre-market Movers: PRST, KOD, GRVY, BEAT, PULM… - Nasdaqnasdaq.com - September 22 at 11:54 AMPULM.OQ - Pulmatrix Inc | Stock Price & Latest News | Reutersreuters.com - September 13 at 12:00 AMPulmatrix Announces Second Quarter 2022 Financial Results and Provides Corporate Update - Yahoo Financefinance.yahoo.com - August 9 at 5:33 PMPulmatrix Announces Second Quarter 2022 Financial Results and Provides Corporate Update - PR Newswireprnewswire.com - August 8 at 4:18 PMPulmatrix Announces Second Quarter 2022 Financial Results and Provides Corporate Updatefinance.yahoo.com - August 8 at 4:18 PMmarketbeat.com - August 5 at 11:28 AM Get Pulmatrix News Delivered to You Automatically Sign up to receive the latest news and ratings for PULM and its competitors with MarketBeat's FREE daily newsletter. Email Address Pentagon contract could send this $2 AI stock soaring (Ad)Whenever the Department of Defense awards a major AI contract... Early investors could see dramatic returns virtually overnight. That's how my readers were able to cash in gains like 133% in just four months on C3.ai... Get all the info here >>> PULM Media Mentions By Week PULM Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PULM News Sentiment▼0.000.43▲Average Medical News Sentiment PULM News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PULM Articles This Week▼10▲PULM Articles Average Week Get Pulmatrix News Delivered to You Automatically Sign up to receive the latest news and ratings for PULM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Lixte Biotechnology News Pasithea Therapeutics News Clever Leaves News ASLAN Pharmaceuticals News Can-Fite BioPharma News eFFECTOR Therapeutics News Chemomab Therapeutics News Trevena News TFF Pharmaceuticals News Tenax Therapeutics News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PULM) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersDid You Get Your Free Bitcoin Yet?Crypto Swap Profitstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersThe #1 Crypto for 2024InvestorPlaceFed launches fourth dollar overhaulStansberry ResearchNew Trump BombshellThe Freeport Society Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pulmatrix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
